Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.

NCT04991116 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.

NCT NCT04991116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
Lead sponsor
Sun Pharmaceutical Industries Limited
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 30, 2022
Completion date
April 30, 2029
Enrollment
529 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis